Genetic and Acquired Determinants of Individual Variability of Response to Antiplatelet Drugs
2003; Lippincott Williams & Wilkins; Volume: 108; Issue: 8 Linguagem: Inglês
10.1161/01.cir.0000088843.52678.8a
ISSN1524-4539
Autores Tópico(s)Platelet Disorders and Treatments
ResumoHomeCirculationVol. 108, No. 8Genetic and Acquired Determinants of Individual Variability of Response to Antiplatelet Drugs Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBGenetic and Acquired Determinants of Individual Variability of Response to Antiplatelet Drugs Andrew I. Schafer Andrew I. SchaferAndrew I. Schafer From the Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia. Originally published26 Aug 2003https://doi.org/10.1161/01.CIR.0000088843.52678.8ACirculation. 2003;108:910–911The efficacy of various antiplatelet agents in preventing cardiovascular and thrombotic complications has been established in large-scale clinical trials. Composite data from such studies tend to mask individual variability in responsiveness to the drugs being investigated. In fact, antiplatelet drugs that are effective and safe in one individual may be ineffective or harmful in another.1See p 921Individual heterogeneity in responsiveness to antiplatelet agents may be due to either inherited or acquired factors. These potential variables include genetic polymorphisms in platelet proteins targeted by the drugs, differences in their pharmacokinetics, drug or other environmental interactions, and the baseline state of platelet function before initiation of treatment. With regard to the latter factor, just as underlying platelet dysfunction increases the risk of bleeding with antiplatelet therapy, it could be predicted that intrinsic platelet hyperaggregability should cause resistance to antiplatelet agents. Indeed, recent studies have demonstrated that pretreatment platelet hyperreactivity is an important determinant of resistance to antiplatelet therapy.2,3 Although intrinsic platelet hyperreactivity may be due to acquired factors, such as accelerated vascular disease (eg, acute coronary syndrome), hypertension, diabetes, or smoking, it can also be caused by genetic factors. A study of sibships drawn from a large, population-based sample without overt cardiovascular disease demonstrated that hereditary factors play an important role in the marked interindividual differences in ex vivo platelet aggregability.4Failure of aspirin to produce expected inhibition of platelet function can be due to genetic determinants or to interference with its antiplatelet action by other drugs. A substantial proportion of individuals treated with aspirin do not achieve the inhibitory response anticipated on laboratory measures of platelet activation and aggregation, a phenomenon termed "aspirin resistance."5,6 The clinical relevance of aspirin resistance was recently demonstrated in a study of stable patients with cardiovascular disease who were found to have a greater than threefold increase in the risk of major adverse events during long-term follow-up compared with those on aspirin who exhibited normal inhibition of platelet aggregation.7 Aspirin resistance has been associated with the PlA2 genotype, a common polymorphism of the platelet glycoprotein (GP) IIIa gene, a component of the GP IIb/IIIa complex that forms the platelet fibrinogen receptor.1,8 Other platelet polymorphisms that could theoretically confer genetic resistance to aspirin include those for the cyclooxygenase isoforms directly targeted by aspirin, other arachidonic acid–mobilizing and –metabolizing enzymes (phospholipases, thromboxane synthase), and other membrane GP receptors involved in initiation of platelet activation. The antiplatelet actions of aspirin can also be antagonized by interactions with certain drugs used concurrently. In particular, nonsteroidal antiinflammatory drugs (NSAIDs), but not selective cyclooxygenase-2 inhibitors, competitively block the ability of low-dose aspirin to cause inhibition of platelet function. Concomitant administration of NSAIDs may thus potentially compromise the cardioprotective effects of aspirin.9 The clinical impact of this drug–drug interaction has yet to be demonstrated.Clinical trials of the different classes of GP IIb/IIIa antagonists have likewise revealed interindividual variability in platelet aggregation inhibition and protective clinical response. The reasons some patients have a subtherapeutic response to GP IIb/IIIa inhibitors are unknown, but polymorphisms in the GP IIb/IIIa complex could potentially contribute to relative resistance to these drugs.10The thienopyridines ticlopidine and clopidogrel inhibit platelet function by irreversibly blocking he binding of adenosine diphosphate (ADP) to its P2Y12 (P2Yac) platelet receptor. Both of these drugs are inactive and require conversion to their active platelet-inhibitory metabolites by the hepatic cytochrome P450 system in vivo. Clopidogrel has a more favorable side effect profile and a more rapid onset of action than does ticlopidine.11,12 Interindividual variability in platelet inhibition by clopidogrel and the occurrence of "clopidogrel resistance" has been recently documented by several groups.2,3,13,14 Although not conclusively demonstrated, one study suggested that clopidogrel resistance increases the risk of coronary stent thrombosis.14 The reasons for variability in response to clopidogrel are unknown, and as yet no genetic determinants (eg, polymorphisms in the platelet ADP receptors) have been identified.Interactions with other drugs that compete with clopidogrel for metabolism to its active form by its predominant cytochrome P450 isoenzyme could significantly reduce clopidogrel's antiplatelet effect. Lau et al15 have reported that coadministration of atorvastatin, an HMG-CoA reductase inhibitor that may share with clopidogrel the cytochrome P450 3A4 (CYP3A4) route of metabolism, reduces the ability of clopidogrel to inhibit platelet aggregation. Because statins are not uncommonly used in patients who require clopidogrel, the clinical relevance of this drug–drug interaction is important to establish. In the present issue of Circulation, Saw et al16 found that the benefit of clopidogrel after percutaneous coronary intervention was similar with the concurrent use of different statins, irrespective of their route of metabolism. The study does provide a degree of reassurance that CYP3A4-metabolized statins do not interfere with clopidogrel's antiplatelet action. However, the results should be interpreted with caution. They are derived from a post hoc efficacy analysis of the CREDO (Clopidogrel for the Reduction of Events During Observation) trial, and as such, they are subject to the pitfalls and biases inherent in such an analysis. Because the data were derived from only a subset of patients selected post hoc on the basis of features observed after randomization into the trial, the results may not apply to a more general population of patients treated prospectively. The results also do not exclude the possibility of drug–drug interactions because the beneficial antiplatelet and antithrombotic properties of statins, unrelated to their direct lipid-lowering actions,17 may have offset any attenuating effects on the antiplatelet action of clopidogrel.Not only can some drugs interfere with the efficacy of antiplatelet agents, but the converse may also occur. For example, the beneficial effects of angiotensin-converting enzyme (ACE) inhibitors in patients with heart failure may be attenuated by concomitant administration of aspirin.18 A price we must pay for the dramatic expansion of our armamentarium of cardiovascular and antithrombotic drugs is the need for increased vigilance for drug interactions that can mitigate the efficacy of one or another in frequently used combinations. It is also becoming increasingly clear that there is considerable intrinsic variability in the responsiveness of individuals to antiplatelet agents, much of which is genetically determined. Point-of-care platelet function testing in acute settings and rational pharmacogenomic approaches will permit more individualized treatment, in some cases requiring dosing changes or the use of alternate drugs to optimize antiplatelet therapy.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.FootnotesCorrespondence to Andrew I. Schafer, MD, Frank Wister Thomas Professor and Chairman, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104. E-mail [email protected] References 1 Quinn MJ, Topol EJ. Common variations in platelet glycoproteins: pharmacogenomic implications. Pharmacogenomics. 2001; 2: 341–352.CrossrefMedlineGoogle Scholar2 Soffer D, Moussa I, Harjai KJ, et al. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Cathet Cardiovasc Intervent. 2003; 59: 21–25.CrossrefMedlineGoogle Scholar3 Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003; 107: 2908–2913.LinkGoogle Scholar4 O'Donnell CJ, Larson MG, Feng D, et al. Genetic and environmental contributions to platelet aggregation: the Framingham Heart Study. Circulation. 2001; 103: 3051–3056.CrossrefMedlineGoogle Scholar5 Eikelboom JW, Hankey GJ. Aspirin resistance: a new independent predictor of vascular events? J Am Coll Cardiol. 2003; 41: 966–968.CrossrefMedlineGoogle Scholar6 Cambria-Kiely JA, Gandhi PJ. Aspirin resistance and genetic polymorphisms. J Thromb Thrombolys. 2002; 14: 51–58.CrossrefMedlineGoogle Scholar7 Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003; 41: 961–965.CrossrefMedlineGoogle Scholar8 Szczeklik A, Undas A, Sanak M, et al. Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa. Br J Haematol. 2000; 110: 965–967.CrossrefMedlineGoogle Scholar9 Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001; 345: 1809–1817.CrossrefMedlineGoogle Scholar10 Wu KK, Willerson JT. Monitoring platelet function in glycoprotein IIb/IIIa inhibitor therapy. Circulation. 2001; 103: 2528–2530.CrossrefMedlineGoogle Scholar11 Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation. 1999; 100: 1667–1672.CrossrefMedlineGoogle Scholar12 Jneid H, Bhatt DL, Corti R, et al. Aspirin and clopidogrel in acute coronary syndromes. Arch Intern Med. 2003; 163: 1145–1153.CrossrefMedlineGoogle Scholar13 Payne DA, Hayes PD, Jones CI, et al. Combined therapy with clopidogrel and aspirin significantly increases the bleeding time through a synergistic antiplatelet action. J Vasc Surg. 2002; 35: 1204–1209.CrossrefMedlineGoogle Scholar14 Muller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003; 89: 783–787.CrossrefMedlineGoogle Scholar15 Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug–drug interaction. Circulation. 2003; 107: 32–37.LinkGoogle Scholar16 Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel–atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation. 2003; 108: 921–924.LinkGoogle Scholar17 Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998; 279: 1643–1650.CrossrefMedlineGoogle Scholar18 Hall D. Controversies in heart failure: are beneficial effects of angiotensin-converting enzyme inhibitors attenuated by aspirin in patients with heart failure? Cardiol Clin. 2001; 19: 597–603.CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By Lee J, Cho Y, Kang H and Han M (2020) Healing of Aneurysm after Treatment Using Flow Diverter Stent : Histopathological Study in Experimental Canine Carotid Side Wall Aneurysm, Journal of Korean Neurosurgical Society, 10.3340/jkns.2019.0067, 63:1, (34-44), Online publication date: 1-Jan-2020. Fan L, Cao J, Liu L, Li X, Hu G, Hu Y and Zhu B (2012) Frequency, Risk Factors, Prognosis, and Genetic Polymorphism of the Cyclooxygenase-1 Gene for Aspirin Resistance in Elderly Chinese Patients with Cardiovascular Disease, Gerontology, 10.1159/000342489, 59:2, (122-131), . Cao J, Liu L, Fan L, Chen T, Hu G, Hu Y, Zhu B, Li J, Wang H and Li X (2012) The prevalence, risk factors and prognosis of aspirin resistance in elderly male patients with cardiovascular disease, The Aging Male, 10.3109/13685538.2012.666584, 15:3, (140-147), Online publication date: 1-Sep-2012. Park K, Jeon K, Kang S, Oh I, Cho H, Lee H, Kang H, Park S, Koo B, Oh B, Park Y and Kim H (2011) Clinical Outcomes of High On-Treatment Platelet Reactivity in Koreans Receiving Elective Percutaneous Coronary Intervention (from Results of the CROSS VERIFY Study), The American Journal of Cardiology, 10.1016/j.amjcard.2011.07.012, 108:11, (1556-1563), Online publication date: 1-Dec-2011. Lippi G, Montagnana M, Danese E, Favaloro E and Franchini M (2011) Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy, Biomarkers in Medicine, 10.2217/bmm.10.119, 5:1, (63-70), Online publication date: 1-Feb-2011. Collyer T, Gray D, Sandhu R, Berridge J and Lyons G (2009) Assessment of platelet inhibition secondary to clopidogrel and aspirin therapy in preoperative acute surgical patients measured by Thrombelastography® Platelet Mapping™, British Journal of Anaesthesia, 10.1093/bja/aep039, 102:4, (492-498), Online publication date: 1-Apr-2009. O'Halloran A, Patterson C, Horan P, Maree A, Curtin R, Stanton A, McKeown P and Shields D (2008) Genetic polymorphisms in platelet-related proteins and coronary artery disease: investigation of candidate genes, including N-acetylgalactosaminyltransferase 4 (GALNT4) and sulphotransferase 1A1/2 (SULT1A1/2), Journal of Thrombosis and Thrombolysis, 10.1007/s11239-008-0196-z, 27:2, (175-184), Online publication date: 1-Feb-2009. Liu Y, Zhang L, Liu Y, Yan F and Zhao Y (2008) Effects of Bulbus allii macrostemi on clinical outcomes and oxidized low-density lipoprotein and plasminogen in unstable angina/non-ST-segment elevation myocardial infarction patients , Phytotherapy Research, 10.1002/ptr.2534, 22:11, (1539-1543), Online publication date: 1-Nov-2008. Airee A, Draper H and Finks S (2008) Aspirin Resistance: Disparities and Clinical Implications, Pharmacotherapy, 10.1592/phco.28.8.999, 28:8, (999-1018), Online publication date: 1-Aug-2008. Gerlach M, Hendrich A, Hueber R, Jost W, Winkler J, Woitalla D and Riederer P (2008) Early Detection of Parkinson's Disease: Unmet Needs, Neurodegenerative Diseases, 10.1159/000113683, 5:3-4, (137-139), . Anavekar N, Tleyjeh I, Anavekar N, Mirzoyev Z, Steckelberg J, Haddad C, Khandaker M, Wilson W, Chandrasekaran K and Baddour L (2007) Impact of Prior Antiplatelet Therapy on Risk of Embolism in Infective Endocarditis, Clinical Infectious Diseases, 10.1086/513197, 44:9, (1180-1186), Online publication date: 1-May-2007. Valles J, Santos M, Fuset M, Moscardo A, Ruano M, Perez F, Piñon M, Breña S and Aznar J (2007) Partial Inhibition of Platelet Thromboxane A2 Synthesis by Aspirin Is Associated With Myonecrosis in Patients With ST-Segment Elevation Myocardial Infarction, The American Journal of Cardiology, 10.1016/j.amjcard.2006.07.058, 99:1, (19-25), Online publication date: 1-Jan-2007. Santos M, Vallés J, Aznar J, Lago A, Sanchez E, Cosin J, Moscardó A, Piñón M, Broekman M and Marcus A (2006) Aspirin therapy for inhibition of platelet reactivity in the presence of erythrocytes in patients with vascular disease, Journal of Laboratory and Clinical Medicine, 10.1016/j.lab.2005.12.005, 147:5, (220-227), Online publication date: 1-May-2006. Tantry U, Bliden K and Gurbel P (2005) Resistance to antiplatelet drugs: current status and future research, Expert Opinion on Pharmacotherapy, 10.1517/14656566.6.12.2027, 6:12, (2027-2045), Online publication date: 1-Oct-2005. Kübler W and Darius H (2005) Primäre Prävention der koronaren Herzkrankheit mit AspirinPrimary prevention of coronary heart disease with aspirin, Zeitschrift für Kardiologie, 10.1007/s00392-005-1309-8, 94:S3, (iii66-iii73), Online publication date: 1-Oct-2005. SZCZEKLIK A, MUSIAŁ J, UNDAS A and SANAK M (2005) Aspirin resistance, Journal of Thrombosis and Haemostasis, 10.1111/j.1538-7836.2005.01372.x, 3:8, (1655-1662), Online publication date: 1-Aug-2005. (2005) Antithrombotic Therapy for Carotid Artery Stenosis Carotid Artery Stenosis, 10.1201/b14239-7, (111-122), Online publication date: 28-Jul-2005. SMITH P (2005) Who can resist aspirin?, Nursing, 10.1097/00152193-200502000-00016, 35:2, (20), Online publication date: 1-Feb-2005. Kimmelstiel C, Badar J, Covic L, Waxman S, Weintraub A, Jacques S and Kuliopulos A (2005) Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage, Thrombosis Research, 10.1016/j.thromres.2004.11.011, 116:1, (55-66), Online publication date: 1-Jan-2005. Coleman J, Wang J and Simon D (2004) Determination of Individual Response to Aspirin Therapy Using the Accumetrics Ultegra RPFA-ASA System, Point of Care: The Journal of Near-Patient Testing & Technology, 10.1097/01.poc.0000127153.41926.ba, 3:2, (77-82), Online publication date: 1-Jun-2004. Ford I and Williams D (2009) Does the use of statins compromise the effectiveness of platelet inhibition by clopidogrel?, Platelets, 10.1080/09537100410001682823, 15:4, (201-205), Online publication date: 1-Jun-2004. August 26, 2003Vol 108, Issue 8 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000088843.52678.8APMID: 12939239 Originally publishedAugust 26, 2003 KeywordsplateletsaspirinEditorialsdrugs, antiplateletPDF download Advertisement
Referência(s)